Reduction of sortilin-1 in Alzheimer hippocampus and in cytokine-stressed human brain cells

NeuroReport

Volumn 18, Issue 11, 2007, Pages 1187-1191

  Zhao, Yuhai ^a   Cui, Jian Guo ^a   Lukiw, Walter J ^a  

^a LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

amyloid precursor protein processing; Alzheimer's disease; Amyloid 42 peptides; Brain gene expression; Cholesterol; Inflammatory signaling; Lipoprotein receptors; SORL1 LR11; Sortilin

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; CYTOKINE; INTERLEUKIN 1BETA; MEMBRANE RECEPTOR; PRESENILIN 1; SORTILIN 1; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN CELL; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HIPPOCAMPUS; HUMAN; HUMAN CELL; HUMAN TISSUE; INCUBATION TIME; LIMBIC CORTEX; NERVE CELL; NEUROFIBRILLARY TANGLE; OCCIPITAL CORTEX; PATHOGENICITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN SECRETION; REDUCTION; SIGNAL TRANSDUCTION; STRESS;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BRAIN; CELL LINE; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HIPPOCAMPUS; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; NEURONS; PEPTIDE FRAGMENTS; POSTMORTEM CHANGES; PRESENILIN-1;

EID: 34250876949     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNR.0b013e32821c56c4     Document Type: Article

References (25)

1. Alzheimer A, Stelzmann RA, Schnitzlein HN, Murtagh FR. An English translation of Alzheimer's 1907 paper, 'Uber eine eigenartige Erkrankung der Hirnrinde'. Clin Anat 1995; 8:429-431.
2. Hardy J. A hundred years of Alzheimer's disease research. Neuron 2006; 52:3-13.
3. Mott RT, Hulette CM. Neuropathology of Alzheimer's disease. Neuroimaging Clin N Am 2005; 15:755-765.
4. Pastorino L, Lu KP. Pathogenic mechanisms in Alzheimer's disease. Eur J Pharmacol 2006; 545:29-38.
5. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. Cell 2005; 120:545-555.
6. Selkoe DJ. Amyloid beta-peptide is produced by cultured cells during normal metabolism: a reprise. J Alzheimers Dis 2006; 9:163-168.
7. Thal DR, Capetillo-Zarate E, Del Tredici K, Braak H. The development of amyloid beta protein deposits in the aged brain. Sci Aging Knowledge Environ 2006; 6:1-11.
8. Chiti F, Dobson CM. Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 2006; 75:333-366.
9. Lukiw WJ. Cholesterol and 24S-hydroxycholesterol trafficking in Alzheimer's disease. Expert Rev Neurother 2006; 6:683-693.
10. Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, et al. Molecular dissection of the interaction between amyloid precursor protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 2006; 45:2618-2628.
11. Spoelgen R, von Arnim CA, Thomas AV, Peltan ID, Koker M, Deng A, et al. Interaction of the cytosolic domains of sorLA/LR11 with the amyloid precursor protein (APP) and beta-secretase beta-site APPcleaving enzyme. J Neurosci 2006; 26:418-428.
12. Cam JA, Bu G. Modulation of beta-amyloid precursor protein trafficking and processing by the low density lipoprotein receptor family. Mol Neurodegener 2006; 1:8-10.
13. Dodson SE, Gearing M, Lippa CF, Montine TJ, Levey AI, Lah JJ. LR11/ SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J Neuropathol Exp Neurol 2006; 65:866-872.
14. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor down-regulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002; 70:462-473.
15. Lukiw WJ. Gene expression profiling in fetal, aged, and Alzheimer hippocampus: a continuum of stress-related signaling. Neurochem Res 2004; 29:1287-1297.
16. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, et al. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer's disease. J Clin Invest 2005; 115:2774-2783.
17. Zhao Y, Jian-Guo Cui JG, Lukiw WJ. Natural secretory products of human neural and microvessel endothelial cells; implications in pathogenic 'spreading' and Alzheimer's disease. Mol Neurobiol 2006; 34:181-192.
18. Morris JC. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 9:173-176.
19. Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett 1993; 162:179-182.
20. Bazan NG, Lukiw WJ. Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells. J Biol Chem 2002; 277:30359-30367.
21. Bohm C, Seibel NM, Henkel B, Steiner H, Haass C, Hampe W. SorLA signaling by regulated intramembrane proteolysis. J Biol Chem 2006; 281: 14547-14553.
22. Cui JG, Hill JM, Zhao Y, Lukiw WJ. Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. NeuroReport 2006; 18:1-5.
23. Scherzer CR, Offe K, Gearing M, Rees HD, Fang G, Heilman CJ, et al. Loss of apolipoprotein E receptor LR11 in Alzheimer disease. Arch Neurol 2004; 61:1200-1205.
24. Shah S, Yu G. sorLA: sorting out APP. Mol Interv 2006; 6:74-76.
25. Marx J. Trafficking protein suspected in Alzheimer's disease. Science 2007; 315:314.